Literature DB >> 32134204

Profibrotic Activation of Human Macrophages in Systemic Sclerosis.

Rajan Bhandari1, Michael S Ball1, Viktor Martyanov2, Dillon Popovich2, Evelien Schaafsma1, Saemi Han1, Mohamed ElTanbouly1, Nicole M Orzechowski3, Mary Carns4, Esperanza Arroyo4, Kathleen Aren4, Monique Hinchcliff4, Michael L Whitfield5, Patricia A Pioli1.   

Abstract

OBJECTIVE: Genome-wide gene expression studies implicate macrophages as mediators of fibrosis in systemic sclerosis (SSc), but little is known about how these cells contribute to fibrotic activation in SSc. We undertook this study to characterize the activation profile of SSc monocyte-derived macrophages and assessed their interaction with SSc fibroblasts.
METHODS: Plasma and peripheral blood mononuclear cells (PBMCs) were obtained from whole blood from SSc patients (n = 24) and age- and sex-matched healthy controls (n = 12). Monocytes were cultured with autologous or allogeneic plasma to differentiate cells into macrophages. For reciprocal activation studies, macrophages were cocultured with fibroblasts using Transwell plates.
RESULTS: The gene expression signature associated with blood-derived human SSc macrophages was enriched in SSc skin in an independent cohort and correlated with skin fibrosis. SSc macrophages expressed surface markers associated with activation and released CCL2, interleukin-6, and transforming growth factor β under basal conditions (n = 8) (P < 0.05). Differentiation of healthy donor monocytes in plasma from SSc patients conferred the immunophenotype of SSc macrophages (n = 13) (P < 0.05). Transwell experiments demonstrated that coculture of SSc macrophages with SSc fibroblasts induced fibroblast activation (n = 3) (P < 0.05).
CONCLUSION: These data demonstrate that the activation profile of SSc macrophages is profibrotic. SSc macrophages are activated under basal conditions and release mediators and express surface markers associated with both alternative and inflammatory macrophage activation. These findings also suggest that activation of SSc macrophages arises from soluble factors in local microenvironments. These studies implicate macrophages as likely drivers of fibrosis in SSc and suggest that therapeutic targeting of these cells may be beneficial in ameliorating disease in SSc patients.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32134204      PMCID: PMC7329566          DOI: 10.1002/art.41243

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  41 in total

Review 1.  Endotoxin tolerance: new mechanisms, molecules and clinical significance.

Authors:  Subhra K Biswas; Eduardo Lopez-Collazo
Journal:  Trends Immunol       Date:  2009-09-24       Impact factor: 16.687

2.  Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression.

Authors:  Xiao-Long Fu; Wei Duan; Chong-Yu Su; Fang-Yuan Mao; Yi-Ping Lv; Yong-Sheng Teng; Pei-Wu Yu; Yuan Zhuang; Yong-Liang Zhao
Journal:  Cancer Immunol Immunother       Date:  2017-08-21       Impact factor: 6.968

3.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

4.  Targeting tumor-associated macrophages as a novel strategy against breast cancer.

Authors:  Yunping Luo; He Zhou; Jörg Krueger; Charles Kaplan; Sung-Hyung Lee; Carrie Dolman; Dorothy Markowitz; Wenyuan Wu; Cheng Liu; Ralph A Reisfeld; Rong Xiang
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

5.  Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma.

Authors:  Nobuyo Higashi-Kuwata; Takamitsu Makino; Yuji Inoue; Motohiro Takeya; Hironobu Ihn
Journal:  Exp Dermatol       Date:  2009-03-03       Impact factor: 3.960

Review 6.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

7.  CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.

Authors:  Michael S Ball; Emilie P Shipman; Hyunjung Kim; Karen T Liby; Patricia A Pioli
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

8.  Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.

Authors:  Alexander V Misharin; Luisa Morales-Nebreda; Paul A Reyfman; Carla M Cuda; James M Walter; Alexandra C McQuattie-Pimentel; Ching-I Chen; Kishore R Anekalla; Nikita Joshi; Kinola J N Williams; Hiam Abdala-Valencia; Tyrone J Yacoub; Monica Chi; Stephen Chiu; Francisco J Gonzalez-Gonzalez; Khalilah Gates; Anna P Lam; Trevor T Nicholson; Philip J Homan; Saul Soberanes; Salina Dominguez; Vince K Morgan; Rana Saber; Alexander Shaffer; Monique Hinchcliff; Stacy A Marshall; Ankit Bharat; Sergejs Berdnikovs; Sangeeta M Bhorade; Elizabeth T Bartom; Richard I Morimoto; William E Balch; Jacob I Sznajder; Navdeep S Chandel; Gökhan M Mutlu; Manu Jain; Cara J Gottardi; Benjamin D Singer; Karen M Ridge; Neda Bagheri; Ali Shilatifard; G R Scott Budinger; Harris Perlman
Journal:  J Exp Med       Date:  2017-07-10       Impact factor: 14.307

9.  Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Jennifer L Hope; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Res Ther       Date:  2017-06-17       Impact factor: 5.156

10.  The Role of M2 Macrophages in the Progression of Chronic Kidney Disease following Acute Kidney Injury.

Authors:  Myung-Gyu Kim; Sun Chul Kim; Yoon Sook Ko; Hee Young Lee; Sang-Kyung Jo; Wonyong Cho
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more
  8 in total

Review 1.  Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

Authors:  Alain Lescoat; David Roofeh; Masataka Kuwana; Robert Lafyatis; Yannick Allanore; Dinesh Khanna
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-01       Impact factor: 10.817

2.  Self-Assembled Human Skin Equivalents Model Macrophage Activation of Cutaneous Fibrogenesis in Systemic Sclerosis.

Authors:  Mengqi Huang; Avi Smith; Matthew Watson; Rajan Bhandari; Lauren M Baugh; Irena Ivanovska; Trishawna Watkins; Irene Lang; Maria Trojanowska; Lauren D Black; Patricia A Pioli; Jonathan Garlick; Michael L Whitfield
Journal:  Arthritis Rheumatol       Date:  2022-05-30       Impact factor: 15.483

3.  Cardiopulmonary arrest due to bronchoscopy-induced Takotsubo syndrome in a patient with antineutrophil cytoplasmic autoantibody-associated lung disease: a case report.

Authors:  Yoshio Okano; Takashi Yamasaki; Ryuichiro Imai; Hiroyasu Okazaki; Yuji Higuchi; Tsutomu Shinohara
Journal:  J Rural Med       Date:  2022-07-01

4.  Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis.

Authors:  Bo Shi; Wenxia Wang; Benjamin Korman; Li Kai; Qianqian Wang; Jun Wei; Swarna Bale; Roberta Goncalves Marangoni; Swati Bhattacharyya; Stephen Miller; Dan Xu; Mahzad Akbarpour; Paul Cheresh; Daniele Proccissi; Demirkan Gursel; Jair Machado Espindola-Netto; Claudia C S Chini; Guilherme C de Oliveira; Johann E Gudjonsson; Eduardo N Chini; John Varga
Journal:  iScience       Date:  2020-12-07

Review 5.  Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights.

Authors:  Bingying Dai; Liqing Ding; Lijuan Zhao; Honglin Zhu; Hui Luo
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810

Review 6.  Role of NLRP3 inflammasome in systemic sclerosis.

Authors:  Cong Lin; Zhixing Jiang; Ling Cao; Hejian Zou; Xiaoxia Zhu
Journal:  Arthritis Res Ther       Date:  2022-08-16       Impact factor: 5.606

Review 7.  Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis.

Authors:  Ezgi Sari; Chao He; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

Review 8.  Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.

Authors:  Andrea De Pieri; Benjamin D Korman; Astrid Jüngel; Karin Wuertz-Kozak
Journal:  Adv Biol (Weinh)       Date:  2021-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.